141 results
424B3
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement
4:53pm
, or may be subject to differing interpretations that may adversely affect a holder of the Common Stock. There can be no assurance the IRS or a court
424B5
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement for primary offering
4:52pm
assumptions and estimates.
We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may … they are sold. There can be no assurance that we will be able to sell any shares under or fully utilize the sales agreement.
We may use any net proceeds from
8-K
92s56l7xjp6 44
29 Mar 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2:41pm
DEF 14C
sr9n 4itu2
18 Mar 24
Information statement
4:59pm
8-K
n4hus 91nzjatgmsjrf
15 Mar 24
Other Events
7:15am
PRE 14C
gluc9
8 Mar 24
Preliminary information
4:31pm
424B3
yhqjuy 6jdqj7ay45na
2 Feb 24
Prospectus supplement
12:00am
8-K
ps0u dt16
24 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1:19pm
8-K
EX-10.2
j36fhzpcaw nttr
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-10.1
eo7510iq7ei 5z9
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm